Select Bibliography

Filter by any of these (after searching):

There are 269 items

Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

Advani, Pooja P. , Ballman, Karla V. , Dockter, Travis J. ... - - J. Clin. Oncol - 2016

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

Advani, Pooja Prem , Ballman, Karla V. , Dockter, Travis J. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - N9831

Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).

Anurag, Meenakshi , Zhu, Mayanne , Huang, Chen , Vasaikar, Suhas ... - - J. Natl. Cancer Inst. - 2019

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1031

Surgical practice patterns following NCCTG N0338 Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer.

Apsey, H. , Roy, V. , Pockaj, B. , Northfelt, D. , Sticca, R. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N0338

Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: Results of ACOSOG (American College Of Surgeons Oncology Group) Z1071 (Alliance) Substudy

Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Armer, Nathan C. ... - - Support Care Cancer - 2019

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Factors Associated With Lymphedema in Women With Node-Positive Breast Cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection

Armer, Jane M. , Ballman, Karla V. , McCall, Linda , Ostby, Pamela L. ... - - JAMA Surg - 2019

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Lymphedema results of Alliance Z1071 (American College of Surgeons Oncology Group [ACOSOG]): Self-reported symptoms and limb volume changes for breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection

Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - ILF - - 2018

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Symptoms and limb changes for breast cancer survivors treated with neoadjuvant chemotherapy: Lymphedema results of ACOSOG Z1071 (Alliance)

Armer, Jane M. , Ballman, Karla , McCall, Linda , Suman, Vera ... - MASCC / ISOO - Supportive Cancer Care - 2017

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression: patient-reported outcomes in the TEXT and SOFT randomised trials

Bernhard, Jürg , Luo, Weixiu , Ribi, Karin , Colleoni, Marco ... - - Lancet Oncol. - 2015

Manuscript - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)

High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy: meta-analysis of individual patient data from 15 randomized adjuvant breast cancer trials

Berry, D. A. , Ueno, N. T. , Johnson, M. M. , Lei, X. , Lopez, V. ... - - Breast Cancer Res. Treat. - 2007

Abstract - Primary Endpoint - Primary Analysis - Breast - INT-0163

High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

Berry, Donald A. , Ueno, Naoto T. , Johnson, Marcella M. ... - - J. Clin. Oncol - 2011

Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Breast - INT-0163

An intensive sequenced adjuvant chemotherapy regimen for breast cancer.

Bhardwaj, S , Holland, J F ... - - Cancer Invest. - 1993

Manuscript - Primary Endpoint - Primary Analysis - Breast - C8743

Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071

Boughey, J. C. , Suman, V. J. , Mittendorf, E. A. , Ahrendt, G. M. ... - SSO - Annals of Surgical Oncology - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOG Z1071 trial

Boughey, J. , Suman, V. , Mittendorf, E. , Ahrendt, G. , Wilke, L. ... - - Cancer Res. - 2012

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)

Boughey, Judy C. , Ballman, Karla V. , Hunt, Kelly K. ... - - J. Clin. Oncol - 2015

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Identification and resection of the clipped node decreases the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from ACOSOG Z1071 (Alliance)

Boughey, Judy C. , Ballman, Karla V. , Le-Petross, Huong T. ... - - Ann. Surg. - 2016

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Tumor Biology and Response to Chemotherapy Impact Breast Cancer-Specific Survival in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Long-term Follow-up from ACOSOG Z1071 (Alliance)

Boughey, Judy C. , Ballman, Karla V. , McCall, Linda M. ... - - Ann. Surg. - 2017

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Methods impacting the false negative rate of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy–results from a prospective trial–ACOSOG Z1071 (Alliance)

Boughey, Judy C. , Ballman, Karla V. , Symmans, William F. ... - SABCS - Cancer Res - 2015

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Axillary Ultrasound after Neoadjuvant Chemotherapy in Patients Presenting with Node-Positive Breast Cancer (T0-T4, N1-2, M0) and its Impact on Sentinel Lymph Node Surgery in ACOSOG Z1071 (Alliance)

Boughey, Judy C. , Ballman, Karla , Hunt, Kelly K. , McCall, Linda M. ... - SIS - Journal of the Senologic International Society - 2014

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Tumor biology and response to chemotherapy impact breast cancer specific survival in node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection: Results from ACOSOG Z1071 (Alliance)

Boughey, Judy C. , Ballman, Karla , McCall, Linda , Byrd, David ... - ASA - - 2017

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z1071

Factors associated with lymphedema in patients/women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary dissection on a prospective clinical trial (Alliance) ACOSOG Z1071

Boughey, Judy C. , Ballman, Karla , McCall, Linda , Kuerer, Henry ... - ASCO - J Clin Oncol - 2018

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Predictors of locoregional recurrence after neoadjuvant chemotherapy and surgery for node positive breast cancer: Results from ACOSOG Z1071 (Alliance)

Boughey, Judy C. , Ballman, Karla , McCall, Linda ... - SABCS - Cancer Res. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) prospective multicenter clinical trial

Boughey, Judy C. , McCall, Linda M. , Ballman, Karla V. ... - - Ann. Surg. - 2014

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Effect of the use of immediate reconstruction on the rates of bilateral mastectomy and adjuvant radiation therapy use in women with node-positive breast cancer treated with neoadjuvant chemotherapy on ACOSOG Z1071 (Alliance).

Boughey, Judy C. , McCall, Linda , Haffty, Bruce , Buchholz, Tom ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)

Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - Ann. Surg. - 2015

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial

Boughey, Judy C. , Suman, Vera J. , Mittendorf, Elizabeth A. ... - - JAMA - 2013

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study

Burstein, H. J. , Barry, W. T. , Cirrincione, C. , Chew, H. K. ... - - Cancer Res. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40302

Endocrine Therapy With or Without Inhibition of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor–Positive Advanced Breast Cancer—CALGB 40302 (Alliance)

Burstein, Harold J. , Cirrincione, Constance T. , Barry, William T. ... - - J. Clin. Oncol - 2014

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40302

Preliminary safety data of a randomized phase III trial comparing a preoperative regimen of FEC-75 alone followed by paclitaxel plus trastuzumab with a regimen of paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab in patients with HER2-positive operable breast cancer (ACOSOG Z1041)

Buzdar, A. U. , Meric-Bernstam, F. , Boughey, J. C. , Leitch, A. M. ... - - J. Clin. Oncol. - 2010

Abstract - Secondary Endpoint - Preliminary Analysis - Breast - ACOSOG-Z1041

ACOSOG Z1041 (Alliance): Definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC -> P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T -> FEC+T) in HER2+ operable breast cancer

Buzdar, A. , Suman, V. , Meric-Bernstam, F. , Leitch, M. , Ellis, M. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Disease-free (DFS) and overall survival (OS) data from ACOSOG Z1041 (Alliance) a randomized neoadjuvant trial comparing FEC followed by Paclitaxel plus Trastuzumab (FEC → P+T) with Paclitaxel plus Trastuzumab followed by FEC plus Trastuzumab (P+T → FEC+T) in HER2-positive operable breast cancer

Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - SABCS - Cancer Res. - 2016

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy

Buzdar, Aman U. , Suman, Vera J. , Meric-Bernstam, Funda ... - - JAMA Oncol - 2019

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

Buzdar, Aman U , Suman, Vera J , Meric-Bernstam, Funda ... - - Lancet Oncol. - 2013

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Comparison of Residual Cancer Burden, American Joint Committee on Cancer staging and Pathologic Complete Response in Breast Cancer after Neoadjuvant Chemotherapy: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Campbell, Jeffrey I. , Yau, Christina , Krass, Polina , Moore, Dan ... - - Breast Cancer Res. Treat. - 2017

Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007

Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).

Carey, Lisa A. , Barry, William Thomas , Pitcher, Brandy ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

Carey, Lisa A. , Berry, Donald A. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40601

Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer

Carey, Lisa A. , Berry, Donald A. , Ollila, David , Harris, Lyndsay ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - C40601

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

Cheng, H , Ballman, K , Vassilakopoulou, M , Dueck, A C ... - - Br. J. Cancer - 2014

Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831

Meta-analysis identifies variants in S1PR1 associated with microtubule targeting agent-induced sensory peripheral neuropathy CALGB 40101 and 40502 (Alliance)

Chua, Katherina C. , Ho, Carol , Mushiroda, Tasei , Jiang, Chen ... - ASCPT - Clinical Pharmacology & Therapeutics - 2018

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - CALGB-40101 , CALGB-40502

Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31

Chumsri, Saranya , Li, Zhuo , Serie, Daniel J. ... - - J. Clin. Oncol - 2019

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831 , NSABP B-31

Effects of Age and Immune Landscape on Outcome in HER2-positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials

Chumsri, Saranya , Serie, Daniel J. , Li, Zhuo ... - - Clin. Cancer Res. - 2019

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N9831 , NSABP B-31

Correlation of high p95HER2:HER2 ratio with poor outcome in two phase II clinical trials of trastuzumab-treated HER2-positive metastatic breast cancer.

Chumsri, Saranya , Sperinde, Jeff , Liu, Heshan , Gligorov, Joseph ... - ASCO - J Clin Oncol - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52

Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52

Clynes, R. , Knutson, K. L. , Ballman, K. , Erskine, C. L. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N0337 , N98-32-52

ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer

Cote, R. , Giuliano, A. E. , Hawes, D. , Ballman, K. V. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831

Crozier, J. A. , Moreno-Aspitia, A. , Ballman, K. V. , Dueck, A. C. ... - - Cancer - 2013

Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831

N0436 (Alliance): A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy

Crozier, Jennifer A. , Advani, Pooja P. , LaPlant, Betsy ... - - Clin. Breast Cancer - 2016

Manuscript - Primary Endpoint - Primary Analysis - Breast - N0436

Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)

Cureton, Elizabeth L. , Yau, Christina , Alvarado, Michael D. ... - - Ann. Surg. Oncol. - 2014

Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)

Dickler, Maura N. , Barry, William T. , Cirrincione, Constance T. ... - - J. Clin. Oncol - 2016

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40503

Phase III Trial Evaluating the Addition of Bevacizumab to Letrozole As First-line Endocrine Therapy for Treatment of Hormone-receptor Positive Advanced Breast Cancer: CALGB 40503 (Alliance)

Dickler, Maura N. , Barry, William Thomas ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40503

Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).

Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Dueck, Amylou C. , Reinholz, Monica M. , Geiger, Xochiquetzal J. ... - - Clin. Cancer Res. - 2013

Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831

Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer)

Dueck, Amylou C. , Sideras, Kostandinos , Sloan, Jeff ... - ISOQOL - Quality of Life Research - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - N1031

Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial

Eiger, D. , Ponde, N. F. , Agbor-Tarh, D. , Moreno-Aspitia, Alvaro ... - ESMO Breast - Annals of Oncology - 2019

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - N063D , ALTTO

ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer

Ellis, M. J. , Buzdar, A. U. , Unzeitig, G. W. , Esserman, L. J. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031

Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study of triage to chemotherapy based on 2 to 4 week Ki67 level >10%

Ellis, M. J. , Suman, V , McCall, L. , Luo, R. , Hoog, J. , Brink, A. ... - AACR - Cancer Res. - 2012

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy ... - - J. Clin. Oncol - 2017

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031B

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Ellis, Matthew J. , Suman, Vera J. , Hoog, Jeremy , Lin, Li ... - - J. Clin. Oncol. - 2011

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031

Genomic predictive biomarkers to anti-HER2 targeted therapies: a combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials

Fernandez-Martinez, Aranzazu , Tanioka, Maki , Fan, Cheng ... - ASCO - J. Clin. Oncol. - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40601

Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoires in HER2-positive breast cancer: a correlative analysis of the CALGB 40601 (Alliance) clinical trial.

Fernandez-Martinez, Aranzazu , Tanioka, Maki , Fan, Cheng ... - ESMO - Ann Oncol - 2019

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601

Molecular Subtypes and Response to Neoadjuvant Chemotherapy in TNBC: Results from Brightness Phase III Study AFT-04 (Alliance)

Filho, Otto Metzger , Stover, Daniel , Asad, Sarah , Ansell, Peter ... - ASCO - J Clin Oncol - 2019

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - AFT-04

Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

Fleming, Gini F , Francis, Prudence A , Láng, István ... - SABCS - Ann. Oncol. - 2017

Abstract - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Francis, P. A. , Pagani, O. , Fleming, G. F. , Walley, B. A. ... - - N. Engl. J. Med. - 2018

Manuscript - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT) , IBCSG-25-02 (TEXT) , S0002

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Francis, Prudence A. , Regan, Meredith M. , Fleming, Gini F. ... - - N. Engl. J. Med. - 2015

Manuscript - Primary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)

Long-Term Follow-Up of TEXT and SOFT Trials of Adjuvant Endocrine Therapies for Premenopausal Women with HR+ Early Breast Cancer

Francis, Prue , Fleming, Gini , Regan, Meredith , Pagani, Olivia ... - SABCS - Cancer Res - 2017

Abstract - Secondary Endpoint - Primary Analysis - Breast - IBCSG-24-02 (SOFT-TEXT)

Association of patient preference for adjuvant chemotherapy (chemo) at baseline (BL) with toxicity, mental health, function, quality of life (QoL) and survival in older women with early stage breast cancer (ESBC) [CALGB 49907 Alliance]

Gajra, Ajeet , McCall, Linda , Muss, Hyman B. , Cohen, Harvey J. ... - SABCS - Cancer Res. - 2015

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-49907

Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer

Garber, Judy E. , Halabi, Susan , Tolaney, Sara M. , Kaplan, Ellen ... - - J Natl Cancer Inst - 2010

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9872

Local and Regional Control in Breast Cancer after Sentinel Node Biopsy without Axillary Lymph Node Dissection: Results from a Randomized Trial

Giuliano, A. E. , Mccall, L. , Beitsch, P. , Whitworth, P. W. ... - ASA - American Surgical Association 130th Annual Meeting - 2010

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1 - 2 N0 M0 breast Cancer who have a positive sentinel node

Giuliano, A. E. , Mccall, L. , Beitsch, P. , Whitworth, P. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis

Giuliano, Armando E. , Ballman, Karla V. , McCall, Linda ... - - JAMA - 2017

Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011

Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-Term Follow-Up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial

Giuliano, Armando E. , Ballman, Karla , McCall, Linda ... - - Ann. Surg. - 2016

Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011

Association of occult metastases in sentinel lymph nodes and bone marrow with survival of women with early-stage invasive breast cancer

Giuliano, Armando E. , Hawes, Debra , Ballman, Karla V. ... - - JAMA - 2011

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

Ten-Year Survival Results of ACOSOG Z0011 (Alliance)

Giuliano, Armando E. , Hunt, Kelly K. , Ballman, Karla. V. ... - ASCO - J. Clin. Oncol. - 2016

Abstract - Secondary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011

Sentinel Lymph Node Dissection With and Without Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial

Giuliano, Armando E. , Hunt, Kelly K. , Ballman, Karla. V. ... - - JAMA - 2011

Manuscript - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: Long-term follow-up from the American College of Surgeons Oncology Group (Alliance) Z0011 Randomized Trial

Giuliano, Armando E , McCall, Linda , Beitsch, Peter ... - ASA - - 2016

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - ACOSOG-Z0011

Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial

Giuliano, Armando E , McCall, Linda , Beitsch, Peter ... - - Ann. Surg. - 2010

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Alliance A011203: A randomized phase II trial of tamoxifen versus Z-endoxifen HCL in postmenopausal women with metastatic estrogen receptor positive, HER2 negative breast cancer

Goetz, Matthew P. , Suman, Vera J , Reid, Joel M. , Kuffel, Mary ... - SABCS - - 2019

Abstract - Primary Endpoint - Primary Analysis - Breast - A011203

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide on breast conservation rates: Surgical results from CALGB 40603 (Alliance).

Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald A. ... - ASA - - 2015

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40603

Impact of Neoadjuvant Therapy on Breast Conservation Rates in Triple- Negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance)

Golshan, Mehra , Cirrincione, Constance T. , Berry, Donald ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary Endpoint - Meta-Analysis Analysis - Breast - CALGB-40601 , CALGB-40603

Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates

Golshan, Mehra , Cirrincione, Constance T. , Sikov, William M. ... - - Ann. Surg. - 2015

Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-40603

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)

Golshan, Mehra , Cirrincione, Constance T. , Sikov, William M. ... - - Breast Cancer Res. Treat. - 2016

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40601

Menstrual Cycle and Surgical Treatment of Breast Cancer: Findings From the NCCTG N9431 Study

Grant, Clive S. , Ingle, James N. , Suman, Vera J. ... - - J Clin Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Breast - N9431

Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy and axillary lymph node dissection: Results from ACOSOG 1071 Clinical Trial

Haffty, Bruce G. , McCall, Linda M. , Ballman, Karla V. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2019

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Radiation use and field design in women with node positive breast cancer treated with preoperative systemic therapy and breast surgery including axillary dissection on a prospective clinical trial ACOSOG Z1071 [Alliance]

Haffty, Bruce G. , McCall, Linda M. , Ballman, Karla V. ... - ASTRO - Int J Radiation Biol Physics - 2015

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: Results from ACOSOG Z1071 (Alliance)

Haffty, Bruce G. , McCall, Linda M. , Ballman, Karla V. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2016

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Impact of radiation on local regional control in women with node positive breast cancer treated with neoadjuvant chemotherapy (NAC) and axillary lymph node dissection (ALND); results from ACOSOG Z1071 (Alliance)

Haffty, Bruce , Ballman, Karla , Hunt, Kelly , McCall, Linda ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

N0733: Phase II trial of capecitabine and lapatinib +/- cixutumumab in HER2 positive breast cancer

Haluska, P. , Reinholz, M. M. , Dueck, A. C. , Linden, H. M. ... - - J. Clin. Oncol. - 2010

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - N0733

Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance).

Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Primary Endpoint - Primary Analysis - Breast - N0733

Impact of Adjuvant Trastuzumab on Local Regional Recurrence; Data from the NCCTG N9831 study.

Halyard, M. Y. , Dueck, A. C. , Pisansky, T. M. , Mclaughlin, S. A. ... - SABCS - Cancer Res. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Changes in left ventricular function after radiation therapy and trastuzumab: analysis of North Central Cancer Treatment Group Phase III Trial N9831.

Halyard, M. , Pisansky, T. M. , Pierce, L. J. , Solin, L. J. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2009

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - NCCTG-N9831

Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831

Halyard, Michele Y. , Pisansky, Thomas M. , Dueck, Amylou C. ... - - J Clin Oncol - 2009

Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Henderson, I Craig , Berry, Donald A , Demetri, George D ... - - J. Clin. Oncol. - 2003

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9344

Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without+/- lapatinib (L) for HER2-positive breast cancer

Hoadley, Katherine A. , Barry, William T. , Pitcher, Brandelyn N. ... - SABCS - Cancer Res - 2015

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601

N0436: A phase II trial of irinotecan plus cetuximab in patients with metastatic breast cancer and prior anthracycline and/or taxane-containing therapy

Hobday, T. J. , Stella, P. J. , Fitch, T. R. , Jaslowski, A. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0436

A North Central Cancer Treatment Group (NCCTG) Phase II Trial of VEGF Trap in Patients With Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline and/or a Taxane.

Hobday, T. , Rowland, K., Jr , Dueck, A. , Northfelt, D. , Lingle, W. ... - ASCO Breast - Breast Cancer Symposium - 2008

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N0537

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer

Hughes, K. S. , Schnaper, L. , Cirrincione, C. T. , Berry, D. A. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-9343

Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343

Hughes, Kevin S. , Schnaper, Lauren A. , Bellon, Jennifer R. ... - - J. Clin. Oncol. - 2013

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-9343

Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer.

Hughes, Kevin S , Schnaper, Lauren A , Berry, Donald ... - - N. Engl. J. Med. - 2004

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-9343

Safety and tolerability of lapatinib ditosylate given concurrently with docetaxel, carboplatin, and trastuzumab (TCHL) as part of adjuvant therapy for patients with HER2+ breast cancer: Pilot data from the North Central Cancer Treatment Group Trial N083E.

Hume, C. Bueno , Moreno-Aspitia, A. , Hillman, D. , Chen, B. ... - - J. Clin. Oncol. - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - NCCTG-N083E

A phase II study evaluating the role of sentinel lymph node surgery and axillary lymph node dissection following preoperative chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis: ACOSOG Z1071

Hunt, K. , Le-Petross, H. T. , Suman, V. , Haffty, B. G. ... - - J. Clin. Oncol. - 2010

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - ACOSOG-Z1071

Factors Associated with Local-Regional Recurrence Following a Negative Sentinel Node Dissection: Results of the ACOSOG Z0010 Trial

Hunt, Kelly K. , Ballman, Karla V. , McCall, Linda M. ... - - Ann. Surg. - 2012

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

Local-Regional Recurrence (LRR) Data from the American College of Surgeons Oncology Group (ACOSOG) Z1041 (Alliance): A Randomized Neoadjuvant Trial of Sequential Versus Concurrent Anthracycline with Trastuzumab and Paclitaxel Plus Trastuzumab in HER2-Positive (HER2+) Breast Cancer (BC)

Hunt, Kelly K. , Suman, Vera J. , Meric-Bernstam, Funda ... - SSO - Ann Surg Oncol - 2019

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1041

Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance).

Hwang, E Shelley , Hyslop, Terry , Hendrix, Laura H ... - - J. Clin. Oncol. - 2020

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-40903

Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) (Alliance) CALGB 40903

Hwang, E. Shelley , Duong, Stephanie , Bedrosian, Isabelle ... - SABCS - Cancer Res - 2017

Abstract - Primary Endpoint - Primary Analysis - Breast - CALGB-40903

MRI Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy: Preliminary Findings of the American College of Radiology Imaging Network (ACRIN) Trial 6657

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - RSNA - Radiological Society of North America 94th Scientific Assembly and Annual Meeting - 2008

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007

Comparison of MRI endpoints for assessing breast cancer response to neoadjuvant treatment: preliminary findings of the American College of Radiology Imaging Network (ACRIN) trial 6657

Hylton, N. M. , Blume, J. , Bernreuter, W. , Pisano, E. , Rosen, M. ... - - Cancer Res. - 2009

Abstract - Primary Endpoint - Preliminary Analysis - Breast - CALGB-150007

MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN trial 6657/CALGB 150007

Hylton, N. M. , Blume, J. , Gastonis, C. , Gomez, R. , Bernreuter, W. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACRIN-6657 , CALGB-150007

Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL

Hylton, Nola M. , Blume, Jeffrey D. , Bernreuter, Wanda K. ... - - Radiology - 2012

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-150007

Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL

Hylton, Nola M. , Gatsonis, Constantine A. , Rosen, Mark A. ... - - Radiology - 2016

Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007

Impact of Tumor-Infiltrating B-Cell Clonal Diversity on Response to Neoadjuvant Therapy in Triple Negative and HER2+ Breast Cancer Treated on CALGB (Alliance) 40601 and 40603

Iglesia, Michael D. , Vincent, Benjamin G. , Serody, Jonathan S. ... - SABCS - Cancer Res. - 2014

Abstract - Secondary Endpoint - Meta-Analysis Analysis - Breast - CALGB-40601 , CALGB-40603

Radiation field design on the ACOSOG Z0011 trial

Jagsi, R. , Ballman, K. , Chadha, M. , Moni, J. , Laurie, F. ... - SABCS - Cancer Res. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial

Jagsi, Reshma , Chadha, Manjeet , Moni, Janaki , Ballman, Karla ... - - J. Clin. Oncol - 2014

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Nomogram-Based Estimate of Axillary Nodal Involvement in ACOSOG Z0011 (Alliance): Validation and Association with Radiation Protocol Variations and Outcomes

Katz, Matthew S. , McCall, Linda , Ballman, Karla , Haffty, Bruce G. ... - ASTRO - Int J Radiat Oncol Biol Phys - 2018

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations.

Katz, Matthew S , McCall, Linda , Ballman, Karla , Jagsi, Reshma ... - - Breast Cancer Res. Treat. - 2020

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Cancer Surveillance Behaviors and Psychosocial Factors Among Long-Term Survivors of Breast Cancer

Katz, Mira L. , Donohue, Kathleen A. , Alfano, Catherine M. ... - - Cancer - 2009

Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-79804

Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)

Kimmick, G. G. , Cirrincione, C. , Duggan, D. B. , Bhalla, K. ... - - Breast Cancer Res. Treat. - 2009

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - C8944

Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831

Knutson, K. L. , Perez, E. A. , Ballman, K. , Erskine, C. L. , Fox, N. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Improved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domain

Knutson, Keith L. , Clynes, Raphael , Shreeder, Barath ... - - Cancer Res. - 2016

Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - N0337 , N98-32-52 , N0938

Associations of HER2-Specific Immunity with Survival During Treatment with Trastuzumab and Chemotherapy in Breast Cancer

Knutson, Keith L. , Clynes, Raphael , Yeramian, Patrick ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - N0337 , N98-32-52 , N0938

Quality of life of early stage breast cancer patients 65 years old or older randomized to standard chemotherapy or capecitabine (CALGB 49907)

Kornblith, A. B. , Archer, L. E. , Lan, L. , Kimmick, G. G. ... - - Cancer Res. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-49907

Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab

Krop, Ian E. , Hillman, David , Polley, Mei , Tanioka, Maki ... - SABCS - Cancer Res - 2018

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40601

A correlative study of cardiac biomarkers and left ventricular ejection fraction (LVEF) from N9831, a phase III randomized trial of chemotherapy and trastuzumab as adjuvant therapy for HER2 positive breast cancer

Kutteh, L.A.. , Hobday, T. J. , Jaffe, A. S. , Laplant, B. R. ... - ASCO - J. Clin. Oncol. - 2007

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Measuring clinically significant chemotherapy-related toxicities using Medicare claims from CALGB breast and lung cancer trial participants

Lamont, E. B. , Herndon, J. E. 2nd , Weeks, J. C. , Henderson, I. C. ... - - J. Clin. Oncol. - 2007

Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - CALGB-70101 , CALGB-9730 , INT-0148

Central review versus local review of axillary ultrasound prior to and after neoadjuvant chemotherapy: Results from the American College of Surgeons Oncology Group Z1071 trial (Alliance)

Le-Petross, H. Carisa , McCall, Linda M. , Hunt, Kelly K. ... - ARRS - - 2019

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Role of axillary ultrasound after neoadjuvant chemotherapy in women with node-positive breast cancer (T1-4, N1-2, M0) at initial diagnosis (ACOSOG Z1071)

Le-Petross, H. T. , Mccall, L. , Hunt, K. , Mittendorf, E. A. ... - - J. Clin. Oncol. - 2012

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Axillary Ultrasound Identifies Residual Nodal Disease After Chemotherapy: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance)

Le-Petross, Huong T. , McCall, Linda M. , Hunt, Kelly K. ... - - AJR Am J Roentgenol - 2018

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z1071

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL

Li, Wen , Arasu, Vignesh , Newitt, David C. , Jones, Ella F. ... - - Tomography - 2016

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACRIN 6657 , CALGB-150007

Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840

Lichtman, S. M. , Hurria, A. , Cirrincione, C. T. , Seidman, A. D. ... - - Ann. Oncol - 2012

Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - CALGB-9342 , CALGB-9840

The Breast Cancer Weight Loss (BWEL) Trial: Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer (Alliance A011401)

Ligibel, Jennifer A. , Barry, William T. , Alfano, Catherine ... - ASCO - J Clin Oncol - 2018

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A011401

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design

Ligibel, Jennifer A. , Barry, William T. , Alfano, Catherine ... - - NPJ Breast Cancer - 2017

Manuscript - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A011401

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance)

Ligibel, Jennifer A. , Cirrincione, Constance T. , Liu, Minetta ... - - J. Natl. Cancer Inst - 2015

Manuscript - Secondary Endpoint - Primary Analysis - Breast - C9741 , CALGB-40902

Physical Activity, Weight and Outcomes in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from CALGB 40502 (Alliance)

Ligibel, LJ , Heubner, JA , Rugo, HS , Burstein, H , Toppmeyer, DL ... - SABCS - Cancer Res - 2018

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-40502

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)

Lin, Cheryl , Buxton, Meredith Becker , Moore, Dan , Krontiras, Helen ... - - Breast Cancer Res. Treat. - 2012

Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007 , CALGB-150012

Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial

Liu, M.C. , Rack, B. , Dueck, A.C. , Hillman, D.W. , Campion, M.B. ... - SABCS - Cancer Res. - 2014

Abstract - Secondary Endpoint - Primary Analysis - Breast - N063D

Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel

Liu, Minetta C. , Demetri, George D. , Berry, Donald A. ... - - Cancer Treat Rev - 2008

Manuscript - Secondary Endpoint - Long-Term-Followup Analysis - Breast - C9141

Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Lucci, Anthony , McCall, Linda Mackie , Beitsch, Peter D ... - - J. Clin. Oncol. - 2007

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0011

Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study

Ma, Cynthia X. , Suman, Vera , Leitch, A. Marilyn , Sanati, Souzan ... - SABCS - Cancer Res. - 2015

Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Breast - A011106

Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082

Marks, L. B. , Cirrincione, C. , Fitzgerald, T. J. , Laurie, F. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2010

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-9082

Evaluating the addition of bevacizumab (Bev) to endocrine therapy as first-line treatment for hormone-receptor positive (HR+)/HER2-negative advanced breast cancer (ABC): Pooled-analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

Martin, Miguel , Loibl, Sibylle , Hyslop, Terry ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40503

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

Martín, M , Loibl, S , Hyslop, T , De la Haba-Rodríguez, J , Aktas, B ... - - Eur. J. Cancer - 2019

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-40503

Concordance of HER2 Central Assessment by Two International Central Laboratories: a ring study within the framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708.

McCullough, AE , Dell'Orto, P , Reinholz, MM , Gelber, RD , Dueck, AC ... - - Cancer Res. - 2010

Abstract - Secondary Endpoint - Primary Analysis - Breast - N063DSS4

100% Concordance between IHC and FISH HER2 Testing Cannot Be Achieved Using N9831 Cohort

Mccullough, A. E. , Chen, B. , Hillman, D. W. , Tenner, K. S. ... - USCAP - Lab Invest - 2010

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - NCCTG-N9831

Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important

Mittendorf, E. , Ballman, K. , Mccall, L. , Hansen, N. , Lucci, A. ... - ASCO - Cancer Res. - 2012

Abstract - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

Evaluation of the Stage IB Designation of the American Joint Committee on Cancer Staging System in Breast Cancer

Mittendorf, Elizabeth A. , Ballman, Karla V. , McCall, Linda M. ... - - J. Clin. Oncol - 2015

Manuscript - Secondary Endpoint - Primary Analysis - Breast - ACOSOG-Z0010

Serum Biomarker Analysis in a Phase II Study of Irinotecan in Refractory Metastatic Breast Cancer

Moreno-Aspitia, A. , Anderson, S. , Reinholz, M. , Dueck, A. ... - SABCS - Cancer Res. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-96-32-55

Serum HER2 (sHER2) levels in early-stage HER2 neu (+) breast cancer (HER2 + BC): Results from the NCCTG adjuvant intergroup trial N9831

Moreno-Aspitia, A. , Dueck, A. , Lingle, W. , Kutteh, L. , Tenner, K. ... - - J. Clin. Oncol. - 2008

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Paclitaxel-Related Peripheral Neuropathy Associated with Improved Outcome of Patients with Early Stage HER2+ Breast Cancer Who Did Not Receive Trastuzumab in the N9831 Clinical Trial

Moreno-Aspitia, A. , Dueck, A. , Patel, T. , Hillman, D. , Tenner, K. ... - SABCS - Cancer Res. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Breast - NCCTG-N9831

Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831

Moreno-Aspitia, A. , Hillman, D. W. , Dueck, A. C. , Carney, W. P. ... - - J. Clin. Oncol. - 2009

Abstract - Secondary Endpoint - Primary Analysis - Breast - N9831

Soluble HER2 (sHER2) levels in HER2-positive breast cancer patients receiving chemotherapy with or without trastuzumab: Results from the NCCTG adjuvant trial N9831

Moreno-Aspitia, A. , Hillman, D. W. , Dyar, S. H. , Tenner, K. S. ... - - Cancer - 2013

Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831

N0937 (Alliance): Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple-negative breast cancer (mTNBC)

Moreno-Aspitia, A. , Liu, H. , Hillman, D. , Rowland, K. M. Jr ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Primary Endpoint - Primary Analysis - Breast - N0937

N0937 (Alliance): Preliminary results of a phase II clinical trial of cisplatin and the novel agent brostallicin in patients with metastatic triple negative breast cancer (mTNBC)

Moreno-Aspitia, A. , Rowland, K. M. Jr , Allred, J. B. , Liu, H. ... - AACR - Cancer Res. - 2012

Abstract - Primary Endpoint - Preliminary Analysis - Breast - N0937

Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer

Moreno-Aspitia, Alvaro , Holmes, Eileen , Jackisch, Christian ... - ASCO - J. Clin. Oncol. - 2017

Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Breast - N063D

Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336

Moreno-Aspitia, Alvaro , Morton, Roscoe F. , Hillman, David W. ... - - J Clin Oncol - 2009

Manuscript - Primary Endpoint - Primary Analysis - Breast - N0336

MRI phenotype and tumor subtype affect breast conservation eligibility and MRI accuracy in the I-SPY 1 trial

Mukhtar, R. A. , Hylton, N. M. ... - - Cancer Res. - 2011

Abstract - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

Mukhtar, Rita A. , Yau, Christina , Rosen, Mark , Tandon, Vickram J. ... - - Ann. Surg. Oncol - 2013

Manuscript - Secondary Endpoint - Primary Analysis - Breast - CALGB-150007

Standard chemotherapy vs capecitabine for older women with early-stage breast cancer: Long-term results of CALGB 49907 (Alliance)

Muss, Hyman B. , Berry, Donald A. , Cirrincione, Constance T. ... - ASCO - J. Clin. Oncol. - 2015

Abstract - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-49907

Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer

Muss, Hyman B. , Berry, Donald A. , Cirrincione, Constance T. ... - - N Engl J Med - 2009

Manuscript - Primary Endpoint - Primary Analysis - Breast - CALGB-49907

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial

Muss, Hyman B. , Polley, Mei-Yin C. , Berry, Donald A. , Liu, Heshan ... - - J. Clin. Oncol - 2019

Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Breast - CALGB-49907

Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.

Muss, Hyman B , Berry, Donald A , Cirrincione, Constance ... - - J. Clin. Oncol. - 2007

Manuscript - Primary Endpoint - Comprehensive Analysis - Breast - C8541 , C9741

Phase II trial combining nab-paclitaxel (NP), gemcitabine (G) and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735

Northfelt, D. W. , Dueck, A. C. , Flynn, T. P. , Stella, P. J. ... - ASCO - J. Clin. Oncol. - 2011

Abstract - Primary Endpoint - Primary Analysis - Breast - N0735

Phase II trial of polyglutamated paclitaxel (PPX) with capecitabine for metastatic breast cancer

Northfelt, D. , Allred, J. , Liu, H. , Hobday, T. , Rodacker, M. ... - - J. Clin. Oncol. - 2008

Abstract - Primary Endpoint - Primary Analysis - Breast - N0437

Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer

Northfelt, DW , Allred, JB , Liu, H , Hobday, TJ , Rodacker, MW ... - - Am. J. Clin. Oncol. - 2014

Manuscript - Primary Endpoint - Primary Analysis - Breast - N0437

Association Studies of Fcγ Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831

Norton, Nadine , Olson, Rebecca M. , Pegram, Mark , Tenner, Kathleen ... - - Cancer Immunol Res - 2014

Manuscript - Secondary Endpoint - Primary Analysis - Breast - N9831

Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance)

Ollila, D. , Berry, D. , Cirrincione, C. , Carey, L. , Amos, K. ... - ASCO - J. Clin. Oncol. - 2013

Abstract - Secondary Endpoint - Primary Analysis - Breast - C40601

Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative)

Ollila, David W , Cirrincione, Constance T , Berry, Donald A ... - - J. Am. Coll. Surg. - 2017

Manuscript - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Breast - CALGB-40601 , CALGB-40603

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL

Olshen, Adam , Wolf, Denise , Jones, Ella F. , Newitt, David ... - - J Med Imaging (Bellingham) - 2018

Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Breast - CALGB-150007

ACOSOG Z1031: A randomized phase II trial comparing exemestane, letrozole and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor positive breast cancer

Olson, J. A. Jr , Babiera, G. V. , Unzeitig, G. , Marcom, P. K. ... - ASCO Breast - Breast Cancer Symposium - 2010

Abstract - Primary Endpoint - Primary Analysis - Breast - ACOSOG-Z1031

Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011.